

JAN 20 2004

Serial No.
10/020,786

Filing Date
13 Dec 2001

Group
~~none~~ 1636

Letters

Examiner

Date Considered _____

5-16-2004


*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USCOMM-DC 80-398.

10/020,786

Applicant Copy

Sheet 1 of 1



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1793R1

Serial No.

10/020,786

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Laura C. Simmons et al.

Filing Date

13 Dec 2001

Group

~~205-48~~ 1636

U.S. PATENT DOCUMENTS

Letters

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
AAZ	86	5,747,662	05.05.98	Simmons et al.	X	X	

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
542	87	0 731 167	11.09.96	EP				
542	88	WO 93/08300	29.04.93	PCT				
542	89	WO 93/19196	30.09.93	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

RECEIVED

JUN 27 2003

TECH CENTER 1600/2900

Examiner

Date Considered

5-16-04

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

5-16-2004

10/020,786

Applicant Copy

Sheet 1 of 4

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1793R1

Serial No.

10/020,786

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Laura C. Simmons et al.

Filing Date

13 Dec 2001

Group

not yet assigned

U.S. PATENT DOCUMENTS

1636 Letters

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
AA	1	4,816,567	28.03.89	Cabilly et al.			
	2	5,264,365	23.11.93	Georgiou et al.			
	3	5,500,362	19.03.96	Robinson et al.			
	4	5,508,192	16.04.96	Georgiou et al.			
	5	5,585,097	17.12.96	Bolt et al.			
	6	5,639,635	17.06.97	Joly et al.			
	7	5,648,237	15.07.97	Carter, P.			
	8	5,821,337	13.10.98	Carter et al.			
	9	5,840,523	24.11.98	Simmons et al.			
	10	6,008,023	28.12.99	Opper et al.			
	11	6,027,888	22.02.00	Georgiou et al.			
	12	6,083,715	04.07.00	Georgiou et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
AA	13	154,316	11.09.85	EP				
	14	401,384	12.12.90	EP				
	15	WO 93/07896	29.04.93	PCT				
	16	WO 93/17715	16.09.93	PCT				
	17	WO 98/48837	05.11.98	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

AA	18	Arie et al., "Chaperone Function of FkpA, A Heat Shock Prolyl Isomerase, in the Periplasm of Escherichia coli." <u>Molecular Microbiology</u> , 39(1):199-210 (2001)						
	19	Armour et al., "Recombinant Human IgG Molecules Lacking Fcγ Receptor I Binding and Monocyte Triggering Activities." <u>European Journal of Immunology</u> , 29(8):2613-2624 (Aug 1999)						
	20	Bachmann., "Derivations and Genotypes of Some Mutant Derivatives of Escherichia coli K-12." <u>Escherichia coli and Salmonella Typhimurium: Cellular and Molecular Biology</u> . (Washington, DC: American Society for Microbiology.), Chapter 72, 2:1190-1219 (1987)						
	21	Barbas III et al., "In Vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity." <u>Proc. Natl. Acad. Sci. USA</u> 91(9):3809-3813 (Apr 26, 1994)						
	22	Bass et al., "Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties" <u>Proteins: Structure, Function, and Genetics</u> 8(4):309-314 (1990)						
	23	Bothmann and Pluckthun., "The Periplasmic Escherichia coli Peptidylprolyl cis,trans-Isomerase FkpA." <u>J. Bio. Chem.</u> 275(22):17100-17105 (Jun 2000)						
	24	Capel et al., "Heterogeneity of Human IgG Fc Receptors." <u>Immunomethods</u> , 4:25-34 (1994)						
AA	25	Carter et al., "High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment." <u>Bio/Technology</u> , 10(2):163-7 (Feb 1992)						

Examiner

Donald R. Kelleher

Date Considered

5-16-2004

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1793R1

Serial No.

10/020,786

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Laura C. Simmons et al.

Filing Date

13 Dec 2001

Group 1636

~~not yet assigned~~

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ADD	26	Carter et al., "Humanization of an Anti-p185HER2 Antibody For Human Cancer Therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89:4285-4289 (May 1992)
	27	Chang et al., "High-Level Secretion of Human Growth Hormone by Escherichia coli." <u>Gene</u> 55:189-196 (1987)
	28	Chari et al., "Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs." <u>Cancer Research</u> 52:127-131 (Jan 1992)
	29	Chen et al., "Chaperone Activity of DsbC." <u>J. Bio. Chem.</u> 274(28):19601-19605 (Jul 1999)
	30	Chothia and Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins" <u>J. Mol. Biol.</u> 196:901-917 (1987)
	31	Clynes et al., "Fc Receptors Are Required in Passive and Active Immunity to Melanoma." <u>Proc. Natl. Acad. Sci. USA</u> 95(2):652-656 (Jan 20, 1998)
	32	Cunningham and Wells, "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis" <u>Science</u> 244:1081-1085 (1989)
	33	Daeron, M., "Fc Receptor Biology" <u>Annual Review of Immunology</u> 15:203-234 (1997)
	34	de Haas et al., "Fcγ Receptors of Phagocytes." <u>J. of Laboratory Clinical Medicine</u> 126:330-341 (1995)
	35	Eigenbrot et al., "X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of VH Residues 59 to 65" <u>Proteins: Structure, Function, and Genetics</u> 18:49-62 (1994)
	36	Fendly, B.M. et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)
	37	Francisco et al., "Agonistic Properties and in Vivo Antitumor Activity of the Anti-CD40 Antibody SGN-14." <u>Cancer Research</u> 60:3225-3231 (Jun 2000)
	38	Friend et al., "Phase I Study of an Engineered Aglycosylated Humanized CD3 Antibody in Renal Transplant Rejection." <u>Transplantation</u> 68(11):1632-1637 (Dec 15, 1999)
	39	Guyer et al., "Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors." <u>J. Immunol.</u> 117(2):587-593 (1976)
	40	Hara et al., "Overproduction of Penicillin-Binding Protein 7 Suppresses Thermosensitive Growth Defect at Low Osmolarity Due to an spr Mutation of Escherichia coli." <u>Micro. Drug Resistance</u> 2(1):63-72 (1996)
	41	Harris., "Therapeutic Monoclonals." <u>Biochemical Society Transactions</u> 23:1035-1038 (1995)
	42	Hawkins et al., "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation" <u>J. Mol. Biol.</u> 226:889-896 (1992)
	43	Henzel et al., "Analysis of Two-Dimensional Gel Proteins by Mass Spectrometry and Microsequencing." <u>Methods: A Companion to Methods Enzymol.</u> 6:239-247 (1994)
	44	Hurle and Gross., "Protein Engineering Techniques for Antibody Humanization." <u>Curr. Op. Biotech.</u> 5:428-433 (1994)
ADD	45	Idusogie et al., "Mapping of the C1q Binding Site on Rituxan, A Chimeric Antibody with a Human IgG1 Fc." <u>J. Immunol.</u> 164:4178-4184 (2000)

Examiner

Donald B. Kelp

Date Considered

5-16-2004

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1793R1Serial No.
10/020,786

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Laura C. Simmons et al.

Filing Date

13 Dec 2001

Group

1636
~~not yet assigned~~

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

46	Isaacs et al., "A Therapeutic Human IgG4 Monoclonal Antibody that Depletes Target Cells in Humans." <u>Clin. Exp. Immunol.</u> 106:427-433 (1996)
47	Jackson et al., "In Vitro Antibody Maturation." <u>J. Immunol.</u> 154(7):3310-3319 (1995)
48	Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)
49	Kikuchi et al., "The Nucleotide Sequence of the Promoter and the Amino-Terminal Region of Alkaline Phosphatase Structural Gene (phoA) of Escherichia coli." <u>Nucleic Acids Research.</u> 9(21):5671-5678 (1981)
50	Kim et al., "Localization of the Site of the Murine IgG1 Molecule That is Involved in Binding to the Murine Intestinal Fc Receptor." <u>European Journal of Immunology.</u> 24:2429-2434 (1994)
51	Kipriyanov and Little., "Generation of Recombinant Antibodies." <u>Mol. Biotech.</u> 12:173-201 (1999)
52	Kostelny et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers" <u>Journal of Immunology</u> 148(5):1547-1553 (1992)
53	Lindmark et al., "Binding of Immunoglobulins to Protein A and Immunoglobulin Levels in Mammalian Sera." <u>J. Immunol. Meth.</u> 62:1-13 (1983)
54	Marks et al., "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling" <u>Bio/Technology</u> 10:779-783 (1992)
55	Matsudaira, P., "Sequence from Picomole Quantities of Proteins Electroblotted onto Polyvinylidene Difluoride Membranes" <u>Journal of Biological Chemistry</u> 262(21):10035-10038 (Jul 25, 1987)
56	Milstein and Cuello, "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (Oct 1983)
57	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains." <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)
58	Picken et al., "Nucleotide Sequence of the Gene for Heat-Stable Enterotoxin II of Escherichia coli." <u>Infection and Immunity.</u> 42(1):269-275 (1983)
59	Pluckthun and Pack., "New Protein Engineering Approaches to Multivalent and Bispecific Antibody Fragments." <u>Immunotechnology.</u> 3:83-105 (June 1997)
60	Pluckthun et al., "Producing Antibodies in Escherichia coli: From PCR to Fermentation." <u>Antibody Engineering: A Practical Approach.</u> Oxford Press, Chapter 10, pps. 203-252 (1996)
61	Pluckthun., "Antibodies From Escherichia coli." <u>The Pharmacol. of Monoclonal Antibodies: Handbook of Exp. Pharmacol.</u> , Rosenberg and Moore, eds., Berlin:Springer-Verlag, Chapter 11, Vol. 3:269-315 (1994)
62	Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" <u>Cancer Research</u> 57(20):4593-4599 (Oct 15, 1997)
63	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)
64	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)
65	Proba et al., "Functional Antibody Single-Chain Fragments From the Cytoplasm of Escherichia coli: Influence of Thioredoxin Reductase (TrxB)." <u>Gene.</u> 159:203-207 (1995)

Examiner

Donald G. Keffe

Date Considered

5-16-2004

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1793R1Serial No.
10/020,786

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Laura C. Simmons et al.

Filing Date

13 Dec 2001

Group 1636

~~not yet assigned~~

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

66	Ramm and Pluckthun., "The Periplasmic Escherichia coli Peptidylprolyl cis,trans Isomerase FkpA." <u>J. Bio. Chem.</u> 275:17106-17113 (2000)
67	Ravetch and Kinet, "Fc Receptors" <u>Annual Review of Immunology</u> 9:457-492 (1991)
68	Reddy et al., "Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4." <u>J. Immunol.</u> 164:1925-1933 (2000)
69	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)
70	Schier et al., "Identification of Functional and Structural Amino-Acid Residues by Parsimonious Mutagenesis." <u>Gene</u> 169:147-155 (1996)
71	Scholtissek and Grosse, "A Cloning Cartridge of λ to Terminator." <u>Nucl. Acids Res.</u> 15(7):3185 (1987)
72	Siebenlist et al., "E. Coli RNA Polymerase Interacts Homologously with Two Different Promoters" <u>Cell</u> 20:269-281 (June 1980)
73	Simmons and Vansura., "Translational Level is a Critical Factor for the Secretion of Heterologous Proteins in Escherichia coli." <u>Nature Biotechnology</u> 14:629-634 (May 1996)
74	Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" <u>The Journal of Immunology</u> 151(4):2296-2308 (Aug 1993)
75	Sutcliffe, J., "Complete Nucleotide Sequence of the Escherichia coli Plasmid pBR322." <u>Cold Spring Harbor Symposia on Quantitative Biology</u> 43:77-90 (1979)
76	Thompson et al., "A Fully Human Antibody Neutralising Biologically Active Human TGF β 2 for Use in Therapy." <u>J. Immunol. Meth.</u> 227:17-29 (1999)
77	Vaswani and Hamilton., "Humanized Antibodies as Potential Therapeutic Drugs." <u>Ann. Allergy Asthma Immunol.</u> 81:105-119 (Aug 1998)
78	Verhoeven, M. et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)
79	Vitetta et al., "Redesigning Nature's Poisons to Create Anti-Tumor Reagents" <u>Science</u> 238:1098-1104 (1987)
80	Yanofsky et al., "The Complete Nucleotide Sequence of the Tryptophan Operon of Escherichia coli." <u>Nucleic Acids Research</u> 9(24):6647-6668 (Nov 1981)
81	Vansura and Simmons, "Nucleotide Sequence Selection for Increased Expression of Heterologous Genes in Escherichia Coli." <u>Methods: A Companion to Methods in Enzymology</u> 4(2):151-158 (1992)
82	Yelton et al., "Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Codon-Based Mutagenesis." <u>J. Immunol.</u> 155:1994-2004 (1995)
83	Zemel-Dreazen and Zamir., "Secretion and Processing of an Immunoglobulin Light Chain in Escherichia coli." <u>Gene</u> 27(3):315-322 (1984)

Examiner

Date Considered

5-16-2004

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.